All In Biotech

Drug Trial Radar · NCT04543617

A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy

A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab With or Without Tiragolumab (Anti-TIGIT Antibody) in Patients With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy

Last checked: Nov 20, 2026Latest source record: Sep 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 760 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

760

Actual

Start

Sep 28, 2020

Primary completion

Jul 22, 2026

Study completion Jul 22, 2026

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Sep 10, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy and safety of tiragolumab plus atezolizumab compared with placebo in participants with unresectable esophageal squamous cell carcinoma (or those who are unable or unwilling to undergo surgery) and whose cancers have not progressed following definitive concurrent chemoradiotherapy (dCRT). Participants will be randomized in a 1:1:1 ratio to receive either tiragolumab plus atezolizumab (Arm A), tiragolumab matching placebo plus atezolizumab (Arm B), or double placebo (Arm C).

Conditions

  • Esophageal Squamous Cell Carcinoma

Interventions

  • TiragolumabDrug

    Tiragolumab at a fixed dose of 600 milligrams (mg) administered by intravenous (IV) infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle.

  • AtezolizumabDrug

    Atezolizumab at a fixed dose of 1200 mg administered by IV infusion Q3W on Day 1 of each 21-day cycle.

  • Tiragolumab Matching PlaceboDrug

    Tiragolumab matching placebo administered by IV infusion Q3W on Day 1 of each 21-day cycle.

  • Atezolizumab Matching PlaceboDrug

    Atezolizumab matching placebo administered by IV infusion Q3W on Day 1 of each 21-day cycle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Arm A vs Arm C: Investigator-Assessed Progression-Free Survival (PFS)Time frame: From randomization to the first occurrence of disease progression or death from any cause, whichever occurs first (up to approximately 6 years)
  2. Arm A vs Arm C: Overall Survival (OS)Time frame: From randomization to death from any cause (up to approximately 6 years)
  3. Arm B vs Arm C: OSTime frame: From randomization to death from any cause (up to approximately 6 years)

Locations

166 sites in 28 countries. Site status is shown where the registry gives one.

  • Florida Cancer Specialists - Fort Myers (Broadway)

    Fort Myers, Florida

  • Cancer Center of Kansas

    Wichita, Kansas

  • Great Lakes Cancer Center

    Williamsville, New York

  • Instituto de Investigaciones Metabolicas (Idim)

    Buenos Aires, Argentina

  • Fundacion Favaloro

    Buenos Aires, Argentina

  • Centro Oncologico Riojano Integral (CORI)

    La Rioja, Argentina

  • Princess Alexandra Hospital

    Woolloongabba, Queensland, Australia

  • Austin Health

    Heidelberg, Victoria, Australia

  • St John of God Hospital

    Subiaco, Western Australia, Australia

  • Tiroler Landeskrankenanstalten Ges.M.B.H.

    Innsbruck, Austria

  • Klinikum Klagenfurt am Wörthersee

    Klagenfurt, Austria

  • Ordensklinikum Linz Barmherzige Schwestern

    Linz, Austria

  • AKH - Medizinische Universität Wien

    Vienna, Austria

  • UZ Antwerpen

    Edegem, Belgium

  • UZ Leuven Gasthuisberg

    Leuven, Belgium

  • CHU de Liège (Sart Tilman)

    Liège, Belgium

  • Anyang Tumor Hosptial

    Anyang, China

  • Cancer Hospital Chinese Academy of Medical Sciences.

    Beijing, China

  • Affiliated Hospital of Bengbu Medical College

    Bengbu, China

  • Hunan Cancer Hospital

    Changsha, China

  • Heping Hospital Affiliated to Changzhi Medical College

    Changzhi, China

  • Changzhou Cancer hospital

    Changzhou, China

  • Sichuan Provincial Cancer Hospital

    Chengdu, China

  • West China Hospital, Sichuan University

    Chengdu, China

  • Chongqing Cancer Hospital

    Chongqing, China

  • Chongqing Sanxia Central Hospital

    Chongqing, China

  • Fujian Cancer Hospital

    Fuzhou, China

  • Sun Yet-sen University Cancer Center

    Guangzhou, China

  • Nanfang Hospital, Southern Medical University

    Guangzhou, China

  • Zhejiang Cancer Hospital

    Hangzhou, China

  • Jieyang People's Hospital

    Jieyang, China

  • Shandong Cancer Hospital

    Jinan, China

  • Affiliated Hospital of Jining Medical University

    Jining, China

  • The First People's Hospital of Lian Yun Gang

    Lianyungang, China

  • Lishui Central Hospital

    Lishui, China

  • The First Affiliated Hospital to Henan University of Science and Technology

    Luoyang, China

  • Affiliated Drum Tower Hospital of Nanjing University Medical School

    Nanjing, China

  • Shanghai Chest Hospital

    Shanghai, China

  • Fudan University Shanghai Cancer Center

    Shanghai, China

  • Cancer Hospital of Shantou University Medical College

    Shantou, China

Showing 40 of 166 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.